Skip to main content
Episurf logo

Episurf — Investor Relations & Filings

Ticker · EPIS ISIN · SE0003491562 LEI · 549300GORBCSMHZB2J75 ST Manufacturing
Open in API
Filings indexed 875 across all filing types
Latest filing 2017-12-11 Regulatory Filings
Country SE Sweden
Listing ST EPIS

About Episurf

https://episurf.com/

Episurf is a medical device company that develops and commercializes patient-specific solutions for treating painful joint injuries. The company's core technology utilizes 3D imaging to create personalized orthopedic implants and surgical instruments tailored to each patient's unique anatomy and cartilage defect. Its primary product line, the Episealer® system, provides minimally invasive implants for treating cartilage and underlying bone lesions in the knee and ankle joints. The objective of this individualized approach is to repair the joint, alleviate pain, and restore function, offering a treatment option for patients, often middle-aged, who are not yet candidates for total joint replacement surgery.

Recent filings

Filing Released Lang Actions
Episurf Medical’s 100th Episealer® implant in Germany
Regulatory Filings Classification · 95% confidence The document is a short announcement from Episurf Medical regarding a milestone (100th implant in Germany) and includes a quote from the CEO. It is not a comprehensive financial report (like 10-K or IR), nor is it a formal earnings release (ER) or a management discussion (MDA). It is a general operational update concerning product adoption and market activity. Since it doesn't fit the specific categories like DIRS, DIV, CAP, or MANG, and it is a general corporate announcement, the most appropriate fallback category is Regulatory Filings (RNS), as it is explicitly stated that the information is made public pursuant to the EU Market Abuse Regulation, which often defaults to RNS if a more specific category isn't applicable.
2017-12-11 English
Episealer® 24 months’ clinical study results accepted for publication in peer-reviewed scientific journal
Regulatory Filings Classification · 95% confidence The document is a short announcement from Episurf Medical regarding the acceptance of their clinical study results for publication in a peer-reviewed journal. It details the study, the positive outcomes, and quotes management. The document explicitly states that the information is being made public pursuant to the EU Market Abuse Regulation and was submitted for publication on a specific date (November 14, 2017). Since this is an announcement about an external event (a publication acceptance) and not the full report itself, and it doesn't fit into specific categories like ER, DIV, or MANG, it falls best under the general regulatory announcement category, RNS (Regulatory Filings), as it is a mandatory disclosure of material information.
2017-11-14 English
24-månadersresultat från klinisk studie med Episealer® accepterad för publikation i expertgranskad vetenskaplig tidskrift
Regulatory Filings Classification · 95% confidence The document is a short announcement (2956 characters) stating that a scientific article detailing 24-month clinical results for the Episealer® implant has been accepted for publication in a peer-reviewed journal ('Knee Surgery, Sports Traumatology, Arthroscopy'). It summarizes key findings (statistical significance for VAS, Tegner, KOOS) and includes quotes from the principal investigator and the CEO. Crucially, it announces the *acceptance* of a publication, rather than being the full scientific paper itself or a standard financial report (like 10-K, IR, ER). Since it is an announcement about a specific event/document release (a scientific publication) and doesn't fit into the primary financial/regulatory categories (like ER, IR, 10-K, DIV, etc.), it falls best under the general 'Regulatory Filings' (RNS) category, which serves as a fallback for significant, non-standard corporate news releases, especially those related to clinical validation which are often disclosed via regulatory channels in Europe. Given the context of clinical data acceptance being announced, RNS is the most appropriate fit among the provided options for a general corporate news release that isn't a standard financial filing or management update.
2017-11-14 Swedish
Major Shareholding Notification 2017
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding and voting rights for an individual ('Pål Ryfors') in the issuer ('Episurf Medical AB'). It explicitly mentions 'Reason for major shareholding notification Buy' and provides 'Before the transaction' and 'After the transaction' figures for shares and voting rights, culminating in a new percentage holding. This structure perfectly matches the definition of a Major Shareholding Notification.
2017-11-13 English
Episurf Medicals vd Pål Ryfors förvärvar aktier motsvarande 3,2% av kapital och 6,8% av röster från huvudägaren Serendipity Ixora
Major Shareholding Notification Classification · 99% confidence The document details a transaction where the CEO (Pål Ryfors) acquired a significant number of shares from a major shareholder (Serendipity Ixora), resulting in a change in ownership percentages and voting rights. This directly relates to insider transactions and changes in significant shareholdings. The definition for 'Director's Dealing' (DIRS) covers personal share transactions by directors and executives. While it also involves a major shareholder, the focus on the CEO's personal acquisition strongly points towards DIRS. It is not an Earnings Release (ER), Interim Report (IR), or a general Regulatory Filing (RNS) because it fits the specific category of insider trading/director dealing. The document length is short (2858 chars), but it is the primary announcement itself, not an announcement *about* another report, so RPA/RNS is less appropriate than the specific category.
2017-11-10 Swedish
Episurf Medical’s CEO Pål Ryfors acquires shares corresponding to 3.2% of capital and 6.8% of votes from main shareholder Serendipity Ixora
Major Shareholding Notification Classification · 99% confidence The document explicitly details a transaction where the CEO, Pål Ryfors, acquires a significant number of shares from the main shareholder, Serendipity Ixora. This involves changes in insider shareholdings and voting rights. This directly matches the definition of 'Director's Dealing' (DIRS), which covers personal share transactions by directors and executives (insider trades). Although it involves shareholding changes (MRQ) and capital structure changes (SHA), the core event is the insider transaction by the CEO. The final paragraph mentions compliance with the EU Market Abuse Regulation, typical for such disclosures.
2017-11-10 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.